Ablynx: Conference call feedback

CORPORATE, Fair Value EUR11 vs. EUR10 (+33%)

News published on September Tuesday 24, 2013
Share on

Following the announcement of the deal with AbbVie, Ablynx held a conference call to detail some elements of the agreement which we show here. There is no doubt that bringing AbbVie as a partner for ALX-0061 is a major achievement for Ablynx. The Biotech company will be in control of the clinical development until 2015 and a potential licensing in. Being in charge of late stage development will help bring significant experience for Ablynx but “ a large part” of the upfront payment will be dedicated to clinical studies. We include economics of the deal in our model and derive a EUR11 fair value.

Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities